Startseite Crystal structure of 7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one-N,N-dimethylformamide (1/1), C18H17NO5
Artikel Open Access

Crystal structure of 7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one-N,N-dimethylformamide (1/1), C18H17NO5

  • Benyong Lou EMAIL logo , Mei Zhang , Yali Huang und Huazhong Wu
Veröffentlicht/Copyright: 2. März 2017

Abstract

C18H17NO5, monoclinic, P21/n (no. 14), a = 6.260(4) Å, b = 20.454(12) Å, c = 12.386(8) Å, β = 97.146(10)°, V = 1573.8(16) Å3, Z = 4, Rgt(F) = 0.0497, wRref(F2) = 0.1214, T = 293 K.

CCDC no.:: 1479812

Table 1

Data collection and handling.

Crystal:Colourless prism
Size:0.20 × 0.15 × 0.15 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:1.0 cm−1
Diffractometer, scan mode:Rigaku CCD, φ and ω
2θmax, completeness:55°, >98%
N(hkl)measured, N(hkl)unique, Rint:12072, 3557, 0.024
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 2778
N(param)refined:227
Programs:CrystalClear [1], SHELX [2]
Table 2

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
O10.81731(18)0.04681(5)0.03899(9)0.0450(3)
O20.24927(19)0.14743(6)−0.00338(10)0.0555(3)
O30.6841(3)−0.02879(7)0.38591(10)0.0603(4)
O40.4245(2)0.29825(7)−0.41674(11)0.0620(4)
O51.0797(2)−0.07186(8)0.38235(13)0.0778(5)
N11.1884(2)−0.13821(7)0.52500(12)0.0528(4)
C30.4208(2)0.11598(7)0.00910(13)0.0393(4)
C20.5740(2)0.11801(7)−0.07069(12)0.0369(3)
C10.7562(3)0.08292(8)−0.05095(13)0.0416(4)
H10.85080.0836−0.10530.050*
C80.6824(2)0.04455(7)0.11793(12)0.0379(3)
C90.4838(2)0.07579(7)0.10446(12)0.0379(3)
C40.3530(3)0.06823(8)0.18806(14)0.0460(4)
H40.21490.08820.18090.055*
C50.4208(3)0.03271(8)0.27948(14)0.0495(4)
H50.32900.02760.33440.059*
C60.6256(3)0.00383(8)0.29236(13)0.0448(4)
C70.7566(3)0.00904(8)0.21086(13)0.0439(4)
H70.8942−0.01120.21810.053*
C100.5389(2)0.16251(7)−0.16570(12)0.0377(3)
C110.3374(3)0.16942(8)−0.22656(13)0.0426(4)
H110.22140.1429−0.21000.051*
C120.3033(3)0.21410(8)−0.31047(13)0.0461(4)
H120.16460.2180−0.35090.055*
C130.7059(3)0.20154(8)−0.19404(13)0.0422(4)
H130.84520.1974−0.15430.051*
C140.6740(3)0.24612(8)−0.27862(13)0.0451(4)
H140.79080.2716−0.29730.054*
C150.4706(3)0.25334(8)−0.33597(13)0.0437(4)
C161.2151(3)−0.10627(9)0.43563(16)0.0592(5)
H161.3513−0.11010.40990.071*
C170.9888(4)−0.13386(14)0.5720(2)0.0841(7)
H17A0.9006−0.09850.53670.126*
H17B1.0200−0.12490.65010.126*
H17C0.9106−0.17530.56110.126*
C181.3566(4)−0.17971(10)0.58000(19)0.0746(6)
H18A1.4843−0.17750.54170.112*
H18B1.3051−0.22490.58030.112*
H18C1.3938−0.16460.65510.112*
H4A0.553(5)0.3185(13)−0.436(2)0.106(9)*
H3A0.815(4)−0.0410(11)0.3872(19)0.083(8)*

The asymmetric unit of the title crystal structure is shown in the figure. Tables 1 and 2 contain details on crystal structure and measurement conditions and a list of the atoms including atomic coordinates and displacement parameters.

Source of material

7-Hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one (daidzein) (254 mg, 1 mmol) was suspended in methanol (20 mL) and some drops of N,N-dimethylformamide were added until daidzein was dissolved completely. The resulting solution was kept in air and colorless block crystals were obtained after several weeks.

Experimental details

The structure was solved by direct methods and refined using the SHELXTL program package [5]. Hydrogen atoms on C atoms were located geometrically (C—H = 0.95 or 0.98 Å) with Uiso(H) = 1.2 Ueq(C) or 1.5 Ueq(C). Hydrogen atoms bonded to O were located by difference maps and the displacement factors were refined freely.

Discussion

In the past twenty years, crystal engineering studies on organic compounds have attracted a large amount of attentions in the field of pharmaceutic science [3]. Flavonoids are a vast group of naturally occurring polyphenolic compounds with health-prolonging effects such as antioxidant, antitumor and anti-inflammatory properties [4]. Some efforts have been made to obtain novel crystalline forms of flavonoids in order to improve their low solubility in water [5]. Daidzein, 7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one, is a isoflavnoid with various physiological benefits [6]. It contains two hydroxy groups in opposite directions in molecular structure, which is in favor of forming a specific hydrogen-bonding network. Until now, there is no crystal structure of daidzein or its adduct reported.

The title compound contains one daidzein molecule and one DMF molecule in the asymmetric unit. The dihedral angle between the 4-hydroxyphenyl ring (C10—C15) and the pyran-2-one moiety (O1/C1—C9) is 43.28(6)°. The daidzein molecule is involved in hydrogen-bonding interactions with DMF [O3⋯O5 = 2.634(2) Å]. The C = O as H-bond acceptor is hydrogen-bonded to the hydroxy O4 as donor [O4⋯O2A = 2.658(2) Å, A = 1/2 + x, 1/2 − y, z − 1/2]. Along the [−1 0 1] direction, daidzein molecules are connected into a V-shaped chain by hydrogen-bonding interactions. The weaker intermolecular interactions between V-shaped chains give rise to the ordered packing structure with a density of 1.381 g/cm3.

Acknowledgement

The authors are grateful to the grant from the Natural Science Foundation of Fujian Province (2015J01599).

References

1 Rigaku/MSC. CrystalClear. Rigaku/MSC Inc., The Woodlands, Texas, USA, (2000).Suche in Google Scholar

2 Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Suche in Google Scholar PubMed

3 Sun, C. C.: Cocrystallization for successful drug delivery. Expert Opin. Drug Delivery 10 (2013) 201–213.10.1517/17425247.2013.747508Suche in Google Scholar PubMed

4 Crozier, A.; Jaganath, I. B.; Clifford, M. N.: Dietaryphenolics: chemistry, bioavailability and effects on health. Nat. Prod. Rep. 26 (2009) 1001–1043.10.1039/b802662aSuche in Google Scholar PubMed

5 Zhu, B.; Wang, J. R.; Mei, X.: Insight into the phase transformation among various solid forms of baicalein. Cryst. Growth Des. 15 (2015) 4959–4968.10.1021/acs.cgd.5b00858Suche in Google Scholar

6 Siegelin, M. D.; Gaiser, T.; Habel, A.; Siegelin, Y.: Daidzein overcomes TRAIL-resistance in malignant glioma cells by modulating the expression of the intrinsic apoptotic inhibitor, bcl-2. Neurosci. Lett. 454 (2009) 223–228.10.1016/j.neulet.2009.03.031Suche in Google Scholar PubMed

Received: 2016-8-31
Accepted: 2017-2-7
Published Online: 2017-3-2
Published in Print: 2017-3-1

©2017 Benyong Lou et al., published by De Gruyter.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Artikel in diesem Heft

  1. Cover and Frontmatter
  2. The crystal structure of triphenylphosphineoxide – 2,5-dichloro-3,6-dihydroxycyclohexa-2,5-diene-1,4-dione (2/1), C42H32Cl2O6P2
  3. Crystal structure of poly-[diaqua-[bis(μ2-hydroxy)-bis(μ4-3,4,5,6-tetrachlorophthalato-κ3O,O′:O′; κ2O′′:O′′′)dilanthanum(III)], C8H3Cl4LaO6
  4. Crystal structure of 1,1′-(3,4-diphenylthieno[2,3-b]thiophene-2,5-diyl)bis[1-phenyl-methanone], C32H20O2S2
  5. Crystal structure of 4a-hydroxy-9-(3,5-dibromo-phenyl)-3,4,4a,5,6,7,9,9a-octahydro-2H-xanthene-1,8-dione, C19H18Br2O4
  6. Crystal structure of 5-hydroxy-4,6,9,10-tetramethyl-1-oxo-6-vinyldecahydro-3a,9-propanocyclopenta[8]annulen-8-yl 2-((2-methyl-1-(3-methylbenzamido)propan-2-yl)thio)acetate, C34H49NO5S
  7. Crystal structure of pyridinium bis(naphthalane-2,3-diolato-κ2O,O′)borate monohydrate, C25H20BNO5
  8. Crystal structure of 1,1′-((1E,1′E)-(((ethane-1,2-diylbis(oxy))bis(2,1-phenylene))bis(azanylylidene))bis(methanylylidene))bis(naphthalen-2-olato)nickel(II), C72H52N4O8Ni2
  9. The crystal structure of 3-(2-acetyl-4-butyramido-phenoxy)-2-hydroxy-N-isopropylpropan-1-aminium tetraphenylborate, C42H49BN2O4
  10. Crystal structure of 4-bromobenzyl (Z)-N′-(adamantan-1-yl)-4-phenylpiperazine-1-carbothioimidate, C28H34BrN3S
  11. Crystal structure of poly-[(μ6-benzene-1,2,4,5-tetracarboxylato)-(μ2-1,2-bis(imidazol-1-ylmethyl)benzene)dicobalt(II)], Co2C24H16N4O8
  12. Crystal structure of catena-(bis(μ2-1, 2-bis(imidazole-1-ylmethyl)benzene-κN:N′)-dichlororido-nickel(II)), C28H28Cl2N8Ni
  13. Crystal structure of (Z)-1-(1,5-dimethyl-1H-pyrazol-3-yl)-3-hydroxy-3-(4-methoxyphenyl)prop-2-en-1-one, C15H16N2O3
  14. Crystal structure of (Z)-1-(1,5-dimethyl-1H-pyrazol-3-yl)-3-hydroxy-3-phenylprop-2-en-1-one, C14H14N2O2
  15. Crystal structure of (E)-2-(4-hydroxy-3-methoxybenzylidene)-6-methoxy-3,4-dihydronaphthalen-1(2H)-one, C19H18O4
  16. Crystal structure of (Z)-1-(1,5-dimethyl-1H-pyrazol-3-yl)-3-(4-ethoxyphenyl)-3-hydroxyprop-2-en-1-one, C16H18N2O3
  17. Crystal structure of (Z)-1-(1,5-dimethyl-1H-pyrazol-3-yl)-3-hydroxy-3-(p-toly)prop-2-en-1-one, C15H16N2O2
  18. Crystal structure of 1-acetyl-3-(3-chlorophenyl)-5-(4-isopropylphenyl)-4,5-dihydro-(1H)-pyrazole, C20H21ClN2O
  19. The crystal structure of 1-methyl-2,4-dinitro-5-iodoimidazole, C4H3IN4O4
  20. The crystal structure of 4-chloro-3,5-dinitroaniline, C6H4ClN3O4
  21. Crystal structure of N,N-dimethyl-N′-(2-methyl-4-oxo-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-3(4H)-yl)formimidamide, C14H18N4OS
  22. Crystal structure of tetrakis(μ2-acetato-κ2O:O′)-bis[μ3-4-chloro-2,6-bis((methylimino)methyl)phenolato-κ2N,O:O,N′]-(μ4-oxido)tetracopper(II), C28H32Cl2Cu4N4O11
  23. Crystal structure of catena-poly[diaqua-bis(μ2-ethane-1,2-diyl-bis(pyridine-3-carboxylate-κ2N:N′))copper(II)] dinitrate, C28H28CuN6O16
  24. Synthesis and crystal structure of catena-poly[(μ2-nicotinato-κ2O,O′: κ1N)-(nitrato-κ1O)-(bis(2-benzimidazol-ylmethyl)amine-κ3N,N′,N′′)lead(II)], C22H18N7O5Pb
  25. The twinned crystal structure of (4SR)-7-benzyl-2,4,8,8-tetramethyl-7,8-dihydroimidazo[5,1-c][1,2,4]triazine-3,6(2H,4H)-dione, C16H20N4O2
  26. Crystal structure of (Z)-3-hydroxy-3-(4-methoxyphenyl)-1-(pyridin-2-yl)prop-2-en-1-one, C15H13NO3
  27. Crystal structure of 2-amino-4-(2,3-dichlorophenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C16H12Cl2N2O2
  28. Crystal structure of catena-poly[(μ2-butane-1,4-diyl-bis(pyridine-3-carboxylato-κN))silver(I)] tetrafluoroborate, C16H16AgN2O4BF4
  29. Crystal structure of poly[diaqua-(1,10-phenanthroline-κ2N,N′)-(μ2-2,5-dihydroxytere-phthalato)-bis(μ4-2,5-dihydroxyterephthalato)dicerium(III)], C24H16CeN2O10
  30. Crystal structure of 5,7,4′-trihydroxy-3,8,3′-trymethoxyflavone, C18H16O8
  31. Crystal structure of N-(3,4-dichlorobenzylidene)-4-methylaniline, C14H11Cl2N
  32. Crystal structure of 4-(3-Methoxy-phenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylic acid ethyl ester, C22H27NO4
  33. Crystal structure of 2-amino-4-(3-fluorophenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C16H13FN2O2
  34. Crystal structure of 1,1,(3,4-dihydroxythieno[2,3-b] thiophene-2,5-diyl)bis(2-bromoethanone), C10H6Br2O4S2
  35. The crystal structure of N,N′-(4,4′-oxydibenzyl)-bisisonicotinamide 3.5 hydrate, C24H24N4O6
  36. Crystal structure of catena-poly[hexakis(μ2-chlorido)-hexakis(4-(1H-pyrazol-5-yl)pyridine-κN)tricadmium(II)], Cd3C48H42Cl6N18
  37. Crystal structure of 2-(4-(dimethylamino)phenyl)-1,3-dimethyl-1H-perimidin-3-ium iodide, C21H22I1N3
  38. Crystal structure of 4-(1,3-dimethyl-2,3-dihydro-1H-perimidin-2-yl)benzonitrile, C20H17N3
  39. Crystal structure of tetrakis(μ2-acetato-κ2O:O′)-bis(2,2′-sulfonyldipyrazine-κ1N)dicopper(II), C24H24Cu2N8O12S2
  40. Crystal structure of 1-(4-chlorophenyl)-6,8-diphenyl-1H-pyrazolo[4,3-c]quinoline, C28H18ClN3
  41. Crystal structure of methyl 3-((1-(2-(methoxycarbonyl)benzyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-naphthoate, C24H21N3O5
  42. Crystal structure of (tris(2-pyridylmethyl)amine-κ4N,N′,N′′,N′′′′)-chloranilato-κO,O′-zinc(II) – methanol (1/1), C25H22Cl2N4O5Zn
  43. Crystal structure of 1,1-dimethyl-3-(4-methoxyphenyl)urea, C10H14N2O2
  44. Crystal structure of 4a-Hydroxy-9-(2-nitro-phenyl)-3,4,4a,5,6,7,9,9a-octahydro-2H-xanthene-1,8-dione, C19H19NO6
  45. Crystal structure of chlorido-(η6–1-isopropyl-4-methyl benzene)-(1-(pyridin-2-yl)-N-(p-tolyl)methanimine-κ2N,N′)ruthenium(II) hexafluorophosphate(V), C23H26ClF6N2PRu
  46. Crystal structure of phenyl(2-phenyl-2,3-dihydro-1H-perimidin-2-yl)methanone, C24H18N2O
  47. Crystal structure of (E)-3-methyl-4-((3-(5-methyl-1-phenyl-1H-1,2,3-triazol-4-yl)-1-phenyl-1H-pyrazol-4-yl)methylene)-1-phenyl-1H-pyrazol-5(4H)-one, C29H23N7O
  48. Crystal structure of 2-(4-(2-butyl-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-6-yl)piperazin-1-yl)-2-oxoethyldiethylcarbamodithioate, C27H34N4O3S2
  49. Crystal structure of poly-[diaqua-bis(μ-4,4′-bipyridine-κ2N:N′)cobalt(II)] bis(4-chlorobenzenesulfonate) – 4,4′-bipyridine – water (1/1/2), C42H40Cl2CoN6O10S2
  50. Crystal structure of (η6-benzene)-(N-(2,6-dimethylphenyl)-1-(pyridin-2-yl)methanimine-κ2N,N′)ruthenium(II) perchlorate monohydrate, C20H20Cl2N2O5Ru
  51. Crystal structure of 4,10,16,22-tetrahydroxy-6,12,18,24-tetramethoxy-2,8,14,20-tetraethylphenylresorcin[4]arene – ethyl acetate (1/1), C68H72O10
  52. Crystal structure of chlorido-(N-(2,5-dichlorophenyl)-1-(pyridin-2-yl)methanimine-κ2N,N′)(η6-1-isopropyl-4-methyl benzene) ruthenium (II) tetrafluoroborate, C22H22Cl3N2BF4Ru
  53. Crystal structure of 3-(5-methyl-1-p-tolyl-1H-1,2,3-triazol-4-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde, a rare Z′ = 3 structure, C20H17N5O
  54. Crystal structure of 5-(5-(4-chlorophenyl)-1-phenyl-1H-pyrazol-3-yl)-N-phenyl-1,3,4-thiadiazol-2-amine, C23H16ClN5S
  55. Crystal structure of 7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one-N,N-dimethylformamide (1/1), C18H17NO5
  56. Crystal structure of halogen-bonded 2-chloro-1,10-phenanthroline—1,4-diiodotetrafluorobenzene (2/1), C30H14Cl2F4I2N4
  57. Crystal structure of 1-(4,4-dimethyl-2,6-dithioxo-1,3,5-triazinan-1-yl)-3-(diethylaminocarbonyl)thiourea, C11H20N6OS3
  58. Crystal structure of methyl 1-(4-fluorobenzyl)-3-phenyl-1H-pyrazole-5-carboxylate, C18H15FN2O2
  59. Crystal structure of 1,1-dimethyl-3-(4-methylphenyl)urea, C10H14N2O
  60. Crystal structure of yttrium gallium antimonide, Y5Ga1.24Sb2.77
  61. Crystal structure of 2-(bis(4-methoxyphenyl)amino)-2-oxoacetic acid, C16H15NO5
Heruntergeladen am 8.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2016-0260/html
Button zum nach oben scrollen